Recently, a screen of compounds for the inhibition of NFκB led to the selection of emetine as a potential anti-leukemia agent, with both in vitro and in vivo effects against human AML cells that were transplanted into NSG mice [84]. This evidence concerns the gene NFKB1 and acute myeloid leukemia.